Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London
Beth Russell(King's College London), Mieke Van Hemelrijck(Ghent University Hospital), Danielle Crawley(Guy's and St Thomas' NHS Foundation Trust), Anna Haire(King's College London), David Wrench(St Bartholomew's Hospital), Deborah Enting(Guy's and St Thomas' NHS Foundation Trust), Richard Sullivan(Precision Spine (United States)), Sophie Papa(Guy's Hospital), Fidelma Cahill(King's College London), Anne Rigg(National Health Service), James Spicer(King's College London), Angela Swampillai(Guy's and St Thomas' NHS Foundation Trust), Ailsa Sita-Lumsden(Guy's and St Thomas' NHS Foundation Trust), Mary Lei(Guy's and St Thomas' NHS Foundation Trust), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Harriet Wylie(King's College London), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Shahram Kordasti(Guy's Hospital), Saoirse Dolly(Guy's and St Thomas' NHS Foundation Trust), Kate Bailey(Guy's and St Thomas' NHS Foundation Trust), Charlotte Moss(Southampton General Hospital), Matthew Streetly(King's College - North Carolina), Elinor J. Sawyer(King's College London), Paul J. Ross(King's College Hospital NHS Foundation Trust), Sheeba Irshad(King's College London), Andrea D’Souza(Guy's and St Thomas' NHS Foundation Trust), Mary Gleeson(Sarah Cannon Research Institute), Paul Fields(St Thomas' Hospital), Sharmistha Ghosh(Guy's and St Thomas' NHS Foundation Trust), Fareen Rahman(Guy's and St Thomas' NHS Foundation Trust), Kamarul Zaki(Guy's and St Thomas' NHS Foundation Trust), Richard Dillon(King's College London), Simon Gomberg(Guy's and St Thomas' NHS Foundation Trust), Kavita Raj(Johns Hopkins Hospital)
Cited by 64
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k